1-7 of 7
Martin Hjorth
Close
Sort by
Journal Articles

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Clinical Trials & Observations
Anders Waage, Peter Gimsing, Peter Fayers, Niels Abildgaard, Lucia Ahlberg, Bo Björkstrand, Kristina Carlson, Inger Marie Dahl, Karin Forsberg, Nina Gulbrandsen, Einar Haukås, Øyvind Hjertner, Martin Hjorth, Torbjörn Karlsson, Lene Meldgaard Knudsen, Johan Lanng Nielsen, Olle Linder, Ulf-Henrik Mellqvist, Ingerid Nesthus, Jürgen Rolke, Maria Strandberg, Jon Hjalmar Sørbø, Finn Wisløff, Gunnar Juliusson, Ingemar Turesson, for the Nordic Myeloma Study Group
Journal: Blood
Blood (2010) 116 (9): 1405–1412.
https://doi.org/10.1182/blood-2009-08-237974
Published: 2010
Journal Articles

Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.

Ulf-Henrik Mellqvist, MD, PhD, Stig Lenhoff, MD, PhD, Martin Hjorth, MD, PhD, Erik Holmberg, PhD, Gunnar Juliusson, MD, PhD, Jon Magnus Tangen, MD, PhD, Jan Westin, MD, PhD, Hans Johnsen, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 793.
https://doi.org/10.1182/blood.V108.11.793.793
Published: 2006
Journal Articles

Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).

Stig Lenhoff, MD, Martin Hjorth, MD, Peter Gimsing, MD, Jon Magnus Tangen, MD, Jan Westin, MD
Journal: Blood
Blood (2004) 104 (11): 924.
https://doi.org/10.1182/blood.V104.11.924.924
Published: 2004
Journal Articles

Intensive Therapy in Multiple Myeloma. Long-Term Follow-Up with Focus on Relapse after Transplantation. The Nordic Myeloma Study Group (NMSG).

Stig Lenhoff, MD, Martin Hjorth, MD, Johan Lanng Nielsen, MD, Ingemar Turesson, MD, Finn Wislöff, MD, Jan Westin, MD
Journal: Blood
Blood (2004) 104 (11): 938.
https://doi.org/10.1182/blood.V104.11.938.938
Published: 2004
Journal Articles

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

Brief Report
Carina Seidel, Øyvind Hjertner, Niels Abildgaard, Lene Heickendorff, Martin Hjorth, Jan Westin, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Anders Waage, Anders Sundan, Magne Børset
Journal: Blood
Blood (2001) 98 (7): 2269–2271.
https://doi.org/10.1182/blood.V98.7.2269
Published: 2001
Journal Articles

Serum syndecan-1: a new independent prognostic marker in multiple myeloma

Carina Seidel, Anders Sundan, Martin Hjorth, Ingemar Turesson, Inger Marie S. Dahl, Niels Abildgaard, Anders Waage, Magne Børset
Journal: Blood
Blood (2000) 95 (2): 388–392.
https://doi.org/10.1182/blood.V95.2.388
Published: 2000
Journal Articles

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study

Stig Lenhoff, Martin Hjorth, Erik Holmberg, Ingemar Turesson, Jan Westin, Johan Lanng Nielsen, Finn Wislöff, Lorentz Brinch, Kristina Carlson, Margaretha Carlsson, Inger-Marie Dahl, Peter Gimsing, Erik Hippe, Hans E. Johnsen, Jon Lamvik, Eva Löfvenberg, Ingerid Nesthus, Stig Rödjer
Journal: Blood
Blood (2000) 95 (1): 7–11.
https://doi.org/10.1182/blood.V95.1.7
Published: 2000